Goldman Sachs’s Ovid Therapeutics OVID Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$93.6K Buy
283,824
+179,389
+172% +$59.2K ﹤0.01% 4891
2025
Q1
$32.6K Sell
104,435
-93,688
-47% -$29.2K ﹤0.01% 4954
2024
Q4
$185K Buy
198,123
+67,844
+52% +$63.3K ﹤0.01% 4682
2024
Q3
$154K Buy
130,279
+3,453
+3% +$4.08K ﹤0.01% 4548
2024
Q2
$97.6K Buy
126,826
+67,842
+115% +$52.2K ﹤0.01% 4504
2024
Q1
$180K Sell
58,984
-2,811
-5% -$8.57K ﹤0.01% 4360
2023
Q4
$199K Buy
61,795
+5,039
+9% +$16.2K ﹤0.01% 4330
2023
Q3
$218K Sell
56,756
-9,366
-14% -$36K ﹤0.01% 4227
2023
Q2
$217K Buy
66,122
+54,948
+492% +$180K ﹤0.01% 4363
2023
Q1
$28.8K Sell
11,174
-3,981
-26% -$10.3K ﹤0.01% 4841
2022
Q4
$28.2K Sell
15,155
-20,919
-58% -$38.9K ﹤0.01% 4858
2022
Q3
$67K Sell
36,074
-7,527
-17% -$14K ﹤0.01% 4998
2022
Q2
$94K Sell
43,601
-1,746
-4% -$3.76K ﹤0.01% 5136
2022
Q1
$143K Sell
45,347
-4,042
-8% -$12.7K ﹤0.01% 5198
2021
Q4
$158K Sell
49,389
-48,156
-49% -$154K ﹤0.01% 5081
2021
Q3
$328K Sell
97,545
-16,027
-14% -$53.9K ﹤0.01% 4610
2021
Q2
$444K Sell
113,572
-637,993
-85% -$2.49M ﹤0.01% 4497
2021
Q1
$3.02M Buy
751,565
+277,020
+58% +$1.11M ﹤0.01% 3030
2020
Q4
$1.1M Buy
474,545
+423,032
+821% +$977K ﹤0.01% 3402
2020
Q3
$296K Sell
51,513
-63,161
-55% -$363K ﹤0.01% 3911
2020
Q2
$845K Sell
114,674
-21,577
-16% -$159K ﹤0.01% 3327
2020
Q1
$406K Buy
136,251
+50,739
+59% +$151K ﹤0.01% 3598
2019
Q4
$355K Buy
85,512
+49,580
+138% +$206K ﹤0.01% 3805
2019
Q3
$116K Sell
35,932
-10,797
-23% -$34.9K ﹤0.01% 4029
2019
Q2
$87K Buy
46,729
+23,210
+99% +$43.2K ﹤0.01% 4019
2019
Q1
$42K Buy
23,519
+7,889
+50% +$14.1K ﹤0.01% 4099
2018
Q4
$38K Sell
15,630
-11,329
-42% -$27.5K ﹤0.01% 3993
2018
Q3
$153K Buy
+26,959
New +$153K ﹤0.01% 3869
2018
Q2
Sell
-14,866
Closed -$105K 4265
2018
Q1
$105K Buy
+14,866
New +$105K ﹤0.01% 4007
2017
Q3
Sell
-87,943
Closed -$923K 4360
2017
Q2
$923K Buy
+87,943
New +$923K ﹤0.01% 3196